Cancer Gene Therapy
Prostate cancer development suppressed by adenoviral-mediated vaccine
Published in Gene Therapy Weekly, August 17th, 2006
"We previously identified a novel p53 target gene, RTVP-1, that possesses unique cytotoxic and immunostimulatory activities which make it potentially useful for cancer gene therapy. To test the therapeutic potential of RTVP-1 in a gene-modified tumor cell-based vaccine model, we used an adenoviral vector capable of efficient transduction and expression of RTVP-1 (AdRTVP-1), together with a highly metastatic mouse prostate cancer cell line (178-2 BMA)," wrote K. Naruishi and colleagues, Baylor...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-08-17)
More Articles from Gene Therapy Weekly
- Cancer Gene Therapy
Survivin downregulation enhances melanoma cell sensitivity to cisplatin - Cancer Gene Therapy
Telomerase-selective oncolytic adenoviral agent enhances antitumor efficacy - Gene Research
Late gene mutants of bacteriophage lambda are an efficient expression vector - RNA Interference
Measles virus and subacute sclerosing panencephalitis virus inhibited by RNA interference - Stem Cell Research
Stem cell factor fused with erythropoietin mimetic peptide expressed in Escherichia coli - Adenovirus Pathogenesis
Adenovirus type 2 and type 5 E1A genes are expressed at different levels - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
